Abstract: Fluorescent labeling of proteins. In particular, membrane-impermeant fluorogenic chromophores being capable of binding reversibly a functional derivative of a Photoactive Yellow Protein (PYP), or a functional fragment thereof, for fluorescently labeling biological molecules of interest, preferably proteins of interest. Especially, 4-hydroxybenzylidene-rhodanine (HBR) analogs of formula (II) as membrane-impermeant fluorogenic chromophores.

Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.

Abstract: A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification wherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(?O)—(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

Abstract: A compound: wherein X1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO2—NH—, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or —CR1R2R3 or alternatively X2—Y2 represents —CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.

Abstract: A microfluidic device for performing physical, chemical or biological treatment to at least one packet without contamination.

Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.

Abstract: The present invention relates to a method for detecting the interaction in a cell between a RNA and a protein, wherein the cell expresses: —the RNA fused to a hairpin, called hairpin-tagged RNA, —the protein fused to a tag, called tagged-protein, —a reporter protein fused to a protein which binds to said hairpin, wherein said reporter protein is a luminescent reporter protein, said method comprises the lysis of the cell and the detection of the complex tagged protein/hairpin-tagged RNA/hairpin binding protein—reporter protein.

Abstract: The invention provides compositions, kits, and methods for inducing growth arrest, differentiation, or senescence of cancer cells that express thymine DNA glycosylase, and treating the cancer accordingly. The methods comprise inhibiting expression or biologic activity of thymine DNA glycosylase in cancer cells. Inhibition of thymine DNA glycosylase in cancer cells may induce the cells to revert to a healthy, non-cancerous phenotype and/or may induce the cells to senesce. Cancer cells include melanoma, lung, prostate, pancreatic, ovarian, brain, colon, recto-sigmoid colon, and breast cancer cells.

Abstract: The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2? and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.

Abstract: The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.

Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.

Abstract: A compound of formula (Ie): wherein Y1 represents an aryl group, X2 represents a —O— group, a —NH— group, a —S— group, a —CO—NH— group, a —NH—CO—NH— group, a —NH—CO— group, a —CH(OH)— group, a —CH(COOH)NH— group, a —CH(COOCH3)NH— group, a —C(OH)(CH2OH)—, a group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a —SO2— group, or a —SO2—NH— group, Y2 represents a hydrogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a —CHC(OH)2, a COORf, wherein Rf represents a hydrogen atom or a (C1-C4)alkyl group, a morpholinyl group, a dihydropyranyl group, a group, a group, a —PO(ORf)(OR?f) group, wherein Rf and R?f independently represents a hydrogen atom or a (C1-C4)alkyl group, an oxetanyl group, a —Si(CH3)3 group, a —NHCOO—(C1-C4)alkyl group, or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.

Abstract: The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods.

Abstract: The manufacture of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof, and use of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof, for treating various conditions, and/or inhibiting replication of HIV-1 in a patient infected with HIV-1, by administering to a patient in need thereof an effective quantity of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides an in vitro method for monitoring interphase nuclear envelope rupture events in a eukaryotic cell or screening or identifying compound capable of increasing or decreasing the intensity and/or frequency of interphase nuclear envelope rupture events in a eukaryotic cell. These methods relate on a protein having a cytosolic non-nuclear localization in interphase and a non-sequence specific DNA binding activity. Interphase nuclear envelope rupture events are characterized by the presence of the protein of the invention in the nucleus of the eukaryotic cell.

Abstract: The present invention provides a new anti-LSP1 (Leukocyte specific protein 1) antibody. This new antibody allows the specific staining of inflammatory dendritic cells and can be used in diagnosis methods or as a medicament when conjugated to a drug.

Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:

Abstract: A microfluidic print head of a printer has a distal face, an injection channel, a suction channel, a groove, and a light source or an optical waveguide. The injection channel is configured to inject an ink onto a substrate and leads onto the distal face by an injection opening The suction channel is configured to suck up the ink and leads onto the distal face by a suction opening. The groove is defined on the distal face and into which the suction opening leads.

Abstract: The invention relates to anti-human follicle-stimulating hormone receptor antibodies. The invention also relates to use of the anti-human follicle-stimulating hormone receptor antibodies in the treatment of cancer. The present invention also relates to a process for detecting cancerous cells and a process for diagnosis cancer. The present invention finds an application in the therapeutic and diagnostic medical technical fields.

Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among: